Zhu Weiwei, Liu Chunquan, Tan Chunting, Zhang Jie
Department of Pulmonary and Critical Care Medicine, Beijing Tiantan Hospital, Capital Medical University, China.
Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, China.
Heliyon. 2023 Dec 11;10(1):e23543. doi: 10.1016/j.heliyon.2023.e23543. eCollection 2024 Jan 15.
Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial disease that cannot be cured, and treatment options for IPF are very limited. Early diagnosis, close monitoring of disease progression, and timely treatment are therefore the best options for patients due to the irreversibility of IPF. Effective markers help doctors judge the development and prognosis of disease. Recent research on traditional biomarkers (KL-6, SP-D, MMP-7, TIMPs, CCL18) has provided novel ideas for predicting disease progression and prognosis. Some emerging biomarkers (HE4, GDF15, PRDX4, inflammatory cells, G-CSF) also provide more possibilities for disease prediction. In addition to markers in serum and bronchoalveolar lavage fluid (BALF), some improvements related to the GAP model and chest HRCT also show good predictive ability for disease prognosis.
特发性肺纤维化（IPF）是一种无法治愈的慢性间质性疾病，IPF的治疗选择非常有限。由于IPF的不可逆性，早期诊断、密切监测疾病进展以及及时治疗因此是患者的最佳选择。有效的标志物有助于医生判断疾病的发展和预后。近期对传统生物标志物（KL-6、SP-D、MMP-7、金属蛋白酶组织抑制因子、CCL18）的研究为预测疾病进展和预后提供了新思路。一些新兴的生物标志物（HE4、生长分化因子15、过氧化物还原酶4、炎症细胞、粒细胞集落刺激因子）也为疾病预测提供了更多可能性。除了血清和支气管肺泡灌洗（BALF）中的标志物外，一些与GAP模型和胸部高分辨率CT（HRCT）相关的改进对疾病预后也显示出良好的预测能力。
